AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Indira IVF Hospital confidentially files for India IPO
ByAinvest
Tuesday, Jul 15, 2025 10:49 pm ET1min read
Indira IVF Hospital confidentially files for India IPO
Indian fertility services provider Indira IVF Hospital has taken a significant step towards going public by filing draft papers confidentially with the country's markets regulator. The news was reported by Reuters and confirmed through various sources, including Bloomberg and Marketscreener.Indira IVF Hospital, founded in 2011, operates over 155 fertility centers and works with 315 IVF specialists across India. The company is backed by private equity firm EQT AB and is seeking to raise approximately 35 billion rupees ($408 million) through its initial public offering (IPO). The IPO will consist solely of existing shares, with EQT AB expected to offload around 29 billion rupees worth of shares. Additionally, three members of the founding family—Ajay Murdia, Kshitiz Murdia, and Nitiz Murdia—will each sell shares valued at about 2 billion rupees [3].
The IPO comes after the company initially submitted a draft prospectus in February but withdrew it in March. The withdrawal was reportedly due to concerns from the Securities and Exchange Board of India (SEBI) about the timing of the IPO, which coincided with the release of a Bollywood biopic based on the company's founder [2, 3].
The IPO is expected to be a significant event in India's healthcare sector, providing investors with an opportunity to invest in a leading fertility services provider. The company's extensive network and expertise in IVF treatments make it a compelling investment option. However, potential investors should carefully consider the risks associated with the healthcare sector and the specific challenges faced by fertility services providers.
Indira IVF Hospital's IPO is being advised by Kotak Mahindra Capital Co., IIFL Capital Services Ltd., JPMorgan Chase & Co., and UBS Group AG [3]. The company's filing with the markets regulator marks a renewed push towards an IPO, with the draft prospectus expected to be submitted later this month [4].
References:
[1] Reuters, "India's Indira IVF Hospital files IPO via confidential route," July 16, 2025, https://www.reuters.com/business/healthcare-pharmaceuticals/indias-indira-ivf-hospital-files-ipo-via-confidential-route-2025-07-16/
[2] Reuters, "Indian fertility services provider Indira IVF Hospital files IPO via confidential route," July 16, 2025, https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TD051:0-india-s-indira-ivf-hospital-files-for-ipo-via-confidential-route/
[3] Bloomberg, "Indira IVF Said to Revive India IPO That May Raise $408 Million," July 15, 2025, https://www.bloomberg.com/news/articles/2025-07-15/indira-ivf-said-to-revive-india-ipo-that-may-raise-408-million
[4] Marketscreener, "Indira IVF Backed by EQT Revives IPO Plans in India," July 15, 2025, https://www.marketscreener.com/quote/stock/EQT-AB-66480635/news/Indira-IVF-Backed-by-EQT-Revives-IPO-Plans-in-India-Bloomberg-News-50509519/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet